How Different Doses of Incretin and Multi-Target Drugs Affect Weight Loss

Dose selection for obesity pharmacotherapy remains less mature than efficacy assessment.

• Average efficacy generally increases with dose, but higher exposure may lead to narrower incremental gains.
• Adverse-event burden and treatment discontinuation can increase with higher doses.
• The maturity of evidence varies across different therapies, and later-stage programs may not be clinically equivalent to those with earlier-phase data.
• The optimal dose for weight loss may differ from that for glycemic control, cardiovascular benefits, and tolerability.
• Response-guided titration is proposed as a framework for future testing, rather than a definitive dosing algorithm.
• Current studies indicate the need for ongoing treatment after weight loss but do not determine a minimum or optimal maintenance dose.

Simplified